Confluence Pharmaceuticals LLC
Restoring Hope and Unlocking Potential: A drug that treats core social and communication impairments caused by Autism & Fragile X Syndrome.
Confluence is developing a clinically discovered, novel therapeutic treatment for patients suffering life-long impairments caused by Autism and Fragile X Syndrome. No drug exists today in this $13 billion market. We have patented IP, human data, 3 potential biomarkers, confirmed FDA plan, and U.S./E.U. Orphan designations. This is a capital efficient development model that presents a low risk, a high return opportunity in a 2-3 year window.